Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Capturing Quality of Life and Priorities for Clinical Research in Parents and Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD PROM)

18 november 2026 uppdaterad av: Children's Hospital of Philadelphia

Chronic kidney disease (CKD) in childhood is a significant burden and reduces the quality of life for both children and their parents. CKD is especially burdensome when it progresses to end stage kidney disease (ESKD, previously referred to as end-stage renal disease or ESRD), placing considerable demands on a childs entire family. Although studies are available for all-cause CKD and for some disease subsets, there is no study capturing quality of life in children or adolescents specifically affected by autosomal recessive polycystic kidney disease (ARPKD). These children are often severely affected prenatally and postnatally have problems due to massive kidney enlargement, hypertension, kidney failure, and portal hypertension. They often need to receive kidney replacement therapy during childhood.

The need to include patients and their lived experience in the design of clinical trials exists for all diseases, but is implemented infrequently, especially in the field of rare diseases. The negative consequences of limited patient/parent input in clinical trial design for rare diseases has been recently highlighted by a report from the International Rare Diseases Research Consortium (IRDiRC).

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

The first primary objective of this study is to assess the quality of life of children affected by autosomal recessive polycystic kidney disease (ARPKD) and their parents, using validated survey instruments.

The second primary objective is to determine priorities of patients, caregivers, and healthcare professionals regarding outcome measures in order to determine a set of core outcomes for future ARPKD-related clinical trials The secondary aim is to validate the use of existing quality of life questionnaire for this cohort of children with ARPKD and to compare their hrQoL to previously published cohorts of children with all-cause chronic kidney disease.

Studietyp

Observationell

Inskrivning (Beräknad)

40

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19146
        • Rekrytering
        • Children's Hospital of Philadelphia
        • Kontakt:
        • Huvudutredare:
          • Lisa Guay-Woodford, M.D.

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

1 sekund till 25 år (Barn, Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

Subjects should be between 0-25 years of age and have an ICD-10 diagnosis code for ARPKD in the CHOP Epic EHR.

Beskrivning

Inclusion Criteria:

  • Subjects should be over 18 years of age and permanently live in the same household as the child/ young person with ARPKD.

Exclusion Criteria:

  • Insufficient understanding of the questions due to intellectual capabilities or language barriers. However, translation by a professional interpreter is permissible.

Lack of written informed consent. Subjects that choose not to have their responses recorded.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: FAMILY_BASED
  • Tidsperspektiv: OTHER

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Patients with ARPKD and their caregivers

Families will be asked to fill out a series of questionnaires

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
PedsQL ESRD Questionnaire
Tidsram: 5 years

PedsQL ESRD Module (quality of life in children with end-stage renal disease) validated questionnaire on health-related QOL for children ≥ 24 months and adults < 25 years with renal disease. 35 questions. Ranking scale (not at all, sometimes, a lot). Items are reverse-scored and linearly transformed to a 0 to 100 scale, where higher scores indicate a better quality of life.

5 years
SDQ (strength and difficulties questionnaire)
Tidsram: 5 years

validated brief emotional and behavioral screening tool. 38 questions. Ranking scale (not true, somewhat true, certainly true). Items divided into five scales of five items each, scored from 0 to 10 per scale, with four problem scales summed into a Total Difficulties score from 0 to 40. Higher scores indicate greater difficulty.

5 years
IFS (impact on family scale)
Tidsram: 5 years

Caregiver burden will be captured by recording the burden on family life with the "Impact on Family Scale"(IFS). 35 questions. Ranking scale (strongly agree, agree, disagree, strongly disagree). Scored by rating each item on a 4-point Likert scale and summing the items to get a total score, where higher scores indicate a greater perceived impact of a child's health condition or disability on the family.

5 years
ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children)
Tidsram: 5 years

Caregiver burden will be captured by recording the burden on family life with ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children). 29 questions. Ranking scale (never, rarely, sometimes, often, always). 5-point rating scale (0 = "never" to 4 = "always") based on the past 7 days, where higher scores indicate better parental quality of life.

5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Lisa Guay-Woodford, M.D., CHOP

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

6 november 2024

Primärt slutförande (Beräknad)

6 november 2030

Avslutad studie (Beräknad)

6 november 2030

Studieregistreringsdatum

Först inskickad

29 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

18 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera